AegirBio AB Logo

AegirBio AB

Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.

AEGIR | ST

Overview

Corporate Details

ISIN(s):
SE0014401121 (+3 more)
LEI:
549300MWGS283WZLYI10
Country:
Sweden
Address:
Scheelevägen 27, 223 63 Lund
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Magnasense AB, formerly AegirBio AB, is a diagnostics company specializing in developing innovative, saliva-based solutions for health monitoring. The company's core technology platform enables the creation of user-friendly, non-invasive tests for personalized diagnostics. Magnasense focuses on preventative care, such as oral health, and chronic disease management, particularly through Therapeutic Drug Monitoring (TDM) to optimize the dosage of biological drugs. Its products are designed for both professional healthcare settings and at-home use, aiming to make precision diagnostic testing more accessible, simple, and convenient for individuals and providers.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all AegirBio AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AegirBio AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AegirBio AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-04-04 Bradley Messmer Other Other 499,829 N/A
2023-01-16 Fredrik Häglund Other Other 45,244 85,511.16 SEK
2022-12-09 Raphaela Heussen Other Other 37,689 N/A
2021-10-27 Martin Linde Other Other 370,000 N/A
2021-10-26 Anders Ingvarsson Other Other 120,000 N/A
2021-09-22 Patrik Elfwing Other Buy 2,000 519,200.00 SEK
2021-09-16 Anders Ingvarsson Other Other 120,000 N/A
2021-06-28 Gunnar Telhammar Other Sell 460 47,288.00 SEK
2021-06-17 Fredrik Häglund Other Other 245,397 1,840,477.50 SEK
2021-06-17 Martin Linde Other Other 160,263 1,169,919.90 SEK

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.